Seropositivity – Page 6 – Communicable Diseases Research

Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2

SARS-CoV-2에 대한 IgG 항체 검출을 위한 단일 표적 분석에 대한 다중 비드 분석 평가

Article

Published on 2022-06-292022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, 치료제,

A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021

2020년 4월부터 2021년 3월까지 헌혈자 보유 표본에서 일반적으로 사용되는 캐나다 SARS-CoV-2 효소 면역분석에 대한 Abbott SARS-CoV-2 IgG II 정량 분석의 정성적 비교

Article

Published on 2022-06-292022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료법,

[키워드] 95% CI 95% confidence interval Abbott Abbott SARS-CoV-2 IgG aggregate Analysis analyzed anti-S anti-SARS-CoV-2 anti-SARS-CoV-2 IgG Anti-spike antibody approach assays Blood donors can be used Canada Characteristics characterized Chicago collected detect ELISAs enzyme-linked immunosorbent assay enzyme-linked immunosorbent assays full-length spike glycoprotein glycoprotein gold gold standard house identify IgG IgG response IgG responses Laboratory methods comparisons nucleocapsid positive provide Qualitative qualitative test RBD Receptor binding Receptor binding domain recognizing reference standard Research retention SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antigens SARS-CoV-2 variant scored sensitivity serology Seropositivity specificity specimen spike spike glycoprotein standard error the SARS-CoV-2 the strongest threshold viral antigens wild-type
[DOI] 10.1128/spectrum.01134-22 PMC 바로가기 [Article Type] Article

Ethnoracial Disparities in SARS-CoV-2 Seroprevalence in a Large Cohort of Individuals in Central North Carolina from April to December 2020

2020년 4월부터 12월까지 중부 노스캐롤라이나의 대규모 개인 집단에서 SARS-CoV-2 혈청 유병률의 인종적 격차

Article

Published on 2022-06-292022-09-11
Journal: mSphere [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus analyzed Antibody titers asymmetric Bayesian inference calculate caused collected coronavirus Course COVID-19 cross-sectional cross-sectional study death dependent on detectable disparity estimate Factor Health Health disparities highest hospital Immunoglobulin increase in individual Latinx likelihood majority neutralization Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers North observation observé Odds ratio PCR-confirmed Population Prevalence respiratory respiratory infection robust SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody SARS-CoV-2 spike protein seropositive individual seropositive individuals seropositive sample Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severity of symptom skewed Spike protein subset Symptoms the United State unique United States university vaccination
[DOI] 10.1128/msphere.00841-21 PMC 바로가기 [Article Type] Article

Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients

리툭시맙 치료 환자에서 COVID-19 백신 접종에 대한 체액 반응 장애의 위험 요인

Observational Study

Published on 2022-06-282022-09-11
Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 진단, 치료기술,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody antibody levels Antibody Response B cell B cells CD19 Characteristics chronic inflammatory rheumatic disorder consecutive patient consecutive patients coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 vaccination cut-off value demographics detectable disease Factor humoral Humoral response identify IgG antibody independent Inflammatory monitoring monotherapy MTX multivariate multivariate analyses negative Odds ratio Patient patients produced receiving recruited respiratory rheumatic disease Rheumatic diseases rituximab RTX SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination seroconversion rate seroconversion rates serology Seropositivity severe acute respiratory syndrome Coronavirus Spike protein Spike proteins therapy two-dose regimen undetectable usual care vaccination were measured
[DOI] 10.1093/rheumatology/keab815 PMC 바로가기 [Article Type] Observational Study

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

건강한 청소년에서 SARS-CoV-2 백신 BNT162b2 및 CoronaVac의 면역원성 및 반응성

Article

Published on 2022-06-282022-09-11
Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술,

The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies

SARS-CoV-2 항체의 혈청학적 평가를 위한 건조된 혈반의 사용

Article

Published on 2022-06-272022-09-11
Journal: Journal of public health (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults alternative antibodies antibody Blood Chain Reaction children cohort study collected coronavirus correlated COVID-19 vaccination detect determine dried blood spot effort ELISA facilitate IgG IgG antibodies IgG antibody IgG level Infectious disease Melbourne Melbourne, Australia Methods participant Participants polymerase chain polymerase chain reaction Population positive public health Public health response Public health responses RBD Receptor-binding domain remained respiratory S1 protein SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 proteins serological Seropositivity serum serum sample serum samples severe acute respiratory syndrome Coronavirus specimen specimens the receptor-binding domain the SARS-CoV-2
[DOI] 10.1093/pubmed/fdab011 PMC 바로가기 [Article Type] Article

Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic

COVID-19 전염병의 첫 해 동안 아칸소에서 소아 SARS-CoV-2 혈청 유병률

Article

Published on 2022-06-222022-09-11
Journal: Journal of the Pediatric Infectious Diseases Socie [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] 2019 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus Adults age antibody association Characteristics Child children clinical care clinics coronavirus coronavirus disease Coronavirus-2 COVID-19 determine Effect Epidemiology ethnic disparity focus highlight Hispanic hospital infected with SARS-CoV-2 lack multivariable regression model multivariable regression models over pandemic Participants pediatric public health Racial racial disparity Recognition Research respiratory SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 seroprevalence SARS-CoV-2 vaccine SARS-CoV-2 variants serology Seropositivity Seroprevalence serum serum sample Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Spread spring tested univariable Year
[DOI] 10.1093/jpids/piac010 PMC 바로가기 [Article Type] Article

SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020-2021

말리 키타 지역의 일상적인 감시 환자, 의료 종사자 및 일반 인구에서 SARS-CoV-2 감염 및 항체 혈청 유병률: 관찰 연구 2020-2021

Observational Study

Published on 2022-06-162022-09-11
Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI age antibody assumed children collected Community contrary COVID-19 COVID-19 infection declined ELISA ELISA test Epidemiology expressed FIVE General population gradually increased HCW HCWs Health health centres health facilities healthcare worker Healthcare workers highest infection rates Local lowest National observation older population outcome participant patients Population positive real-time RT-PCR respiratory respiratory infections routine RT-PCR SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 transmission Seropositivity Serosurvey serum sample serum samples Surveillance tested total antibodies total antibody West widespread
[DOI] 10.1136/bmjopen-2021-060367 PMC 바로가기 [Article Type] Observational Study

Rapid Emergence and Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Gamma (P.1) Variant in Haiti

아이티에서 중증급성호흡기증후군 코로나바이러스 2 감마(P.1) 변이의 급속한 출현 및 확산

Article

Published on 2022-06-102022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종,

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구

Clinical Trial

Published on 2022-06-092022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year
[DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial